You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches
Pulmonology

OCS Use in Severe Asthma Is Often Associated With Adverse Effects

Uncover the risks associated with OCS in patients with severe asthma.

/0
Tags
oral corticosteroidsadverse events
MAT-US-2309869 v2.0 P - Exp. Date 09/25/2025

Related resources

ADVENT On Air | Common Drivers of Type 2 Inflammatory Diseases
Type 2 Inflammation
audio

ADVENT On Air | Common Drivers of Type 2 Inflammatory Diseases

Worsening Disease Results in a Vicious Cycle of COPD
Pulmonology
interactivity

Worsening Disease Results in a Vicious Cycle of COPD

Chronic Obstructive Pulmonary Disease: Disease Burden & Heterogeneity
Pulmonology
interactivity

Chronic Obstructive Pulmonary Disease: Disease Burden & Heterogeneity

Chronic Spontaneous Urticaria: Disease Overview
Dermatology
interactivity

Chronic Spontaneous Urticaria: Disease Overview

Adult Asthma Interactive Patient Cases
Pulmonology
interactivity

Adult Asthma Interactive Patient Cases

Effect of Type 2 Inflammation on Skin Barrier Function in AD​
Dermatology
interactivity

Effect of Type 2 Inflammation on Skin Barrier Function in AD​

Prurigo Nodularis (PN) Case Studies
Dermatology
interactivity

Prurigo Nodularis (PN) Case Studies

The Pathophysiology of Type 2 Inflammation in CRSwNP
Rhinology
interactivity

The Pathophysiology of Type 2 Inflammation in CRSwNP

Eosinophilic Esophagitis (EoE) Interactive Patient Case
Gastroenterology
interactivity

Eosinophilic Esophagitis (EoE) Interactive Patient Case

Type 2 Inflammation and Neuronal Sensitization in AD and PN
Dermatology
interactivity

Type 2 Inflammation and Neuronal Sensitization in AD and PN

Type 2 Inflammation in CRSwNP: Interactive Patient Case
Rhinology
interactivity

Type 2 Inflammation in CRSwNP: Interactive Patient Case

The Role of Type 2 Inflammation in Multiple Disease Trajectories
Type 2 Inflammation
interactivity

The Role of Type 2 Inflammation in Multiple Disease Trajectories

Type 2 Inflammation Digital Assessment Tool
Pulmonology
interactivity

Type 2 Inflammation Digital Assessment Tool

EoE: A Chronic, Progressive, Type 2 Inflammatory Disease
Gastroenterology
Infographic

EoE: A Chronic, Progressive, Type 2 Inflammatory Disease

Importance of Assessing Key Disease Domains in EoE Infographic
Gastroenterology
Infographic

Importance of Assessing Key Disease Domains in EoE Infographic

ADVENT On Air | Clinical Perspective on Pediatric Patients With Atopic Dermatitis
Dermatology
audio

ADVENT On Air | Clinical Perspective on Pediatric Patients With Atopic Dermatitis

ADVENT On Air | Defining AD in Pediatric Patients
Dermatology
audio

ADVENT On Air | Defining AD in Pediatric Patients

ADVENT On Air | Getting to the Diagnosis of AD in Pediatric Patients
Dermatology
audio

ADVENT On Air | Getting to the Diagnosis of AD in Pediatric Patients

OCS Use in Severe Asthma Is Often Associated With Adverse Effects
Pulmonology
Infographic

OCS Use in Severe Asthma Is Often Associated With Adverse Effects

GINA Guidelines For Improved Outcomes With Effective Management of Pediatric Asthma
Pulmonology
interactivity

GINA Guidelines For Improved Outcomes With Effective Management of Pediatric Asthma

Chronic Spontaneous Urticaria (CSU) Interactive Patient Case
Dermatology
interactivity

Chronic Spontaneous Urticaria (CSU) Interactive Patient Case

ADVENT On Air | What Is the Future Outlook for Remission in Pediatric Severe Asthma?
Pulmonology
audio

ADVENT On Air | What Is the Future Outlook for Remission in Pediatric Severe Asthma?

Type 2 Inflammation and Infections
Type 2 Inflammation
slide presentation

Type 2 Inflammation and Infections

ADVENT On Air | Loss of Smell in CRSwNP Patients
Rhinology
audio

ADVENT On Air | Loss of Smell in CRSwNP Patients

AD Static Infographic
Dermatology
Infographic

AD Static Infographic

Atopic Dermatitis (AD) and Prurigo Nodularis (PN): Distinct Diseases with Shared Characteristics
Dermatology
interactivity

Atopic Dermatitis (AD) and Prurigo Nodularis (PN): Distinct Diseases with Shared Characteristics

Chronic Spontaneous Urticaria (CSU): Disease Overview
Dermatology
Infographic

Chronic Spontaneous Urticaria (CSU): Disease Overview

CRSwNP Significantly Affects the Quality of Life of CRSwNP Patients
Rhinology
interactivity

CRSwNP Significantly Affects the Quality of Life of CRSwNP Patients

Learn more about how dysregulated type 2 inflammation contributes to polymorphous lesions and dermal epidermal splitting in bullous pemphigoid
Dermatology
Infographic

Bullous Pemphigoid (BP) Pathophysiology Infographic

Skin Barrier Dysfunction and Type 2 Inflammation in Atopic Dermatitis
Dermatology
videoanimation

Skin Barrier Dysfunction and Type 2 Inflammation in Atopic Dermatitis

ADVENT On Air | Remission in CRSwNP
Rhinology
audio

ADVENT On Air | Remission in CRSwNP

Pediatric EoE Disease Burden Infographic
Gastroenterology
Infographic

Pediatric EoE Disease Burden Infographic

FeNO: A Biomarker of Type 2 Inflammation in Pediatric Asthma Patients
Pulmonology
Infographic

FeNO: A Biomarker of Type 2 Inflammation in Pediatric Asthma Patients

Is Pediatric AD Linked to Other Allergic Diseases?
Dermatology
expert video

Is Pediatric AD Linked to Other Allergic Diseases?

Inflamm-aging: Systemic Inflammation and Frailty in Older Adults
Dermatology
expert video

Inflamm-aging: Systemic Inflammation and Frailty in Older Adults

New Data on the Systemic (Multi-Organ) Burden of AD in Children and the Need for Early Intervention
Dermatology
expert video

New Data on the Systemic (Multi-Organ) Burden of AD in Children and the Need for Early Intervention

A Tale of Two Itches: Bridging the Gap With Type 2 Inflammation in Prurigo Nodularis and Chronic Spontaneous Urticaria
Dermatology
expert video

A Tale of Two Itches: Bridging the Gap With Type 2 Inflammation in Prurigo Nodularis and Chronic Spontaneous Urticaria

Skin Dyspigmentation In Prurigo Nodularis (PN)
Dermatology
interactivity

Skin Dyspigmentation In Prurigo Nodularis (PN)

Long-term Impacts of AD and the Potential Benefit of Early Intervention
Dermatology
expert video

Long-term Impacts of AD and the Potential Benefit of Early Intervention

Practical Considerations in Older Patients with AD
Dermatology
expert video

Practical Considerations in Older Patients with AD

ERS 2023 | Heterogeneity of Inflammatory Pathways in COPD
Pulmonology
expert video

ERS 2023 | Heterogeneity of Inflammatory Pathways in COPD

GOLD 2023 | Beyond a One Size Fits All Approach: Recognizing the Heterogeneity of COPD
Pulmonology
expert video

GOLD 2023 | Beyond a One Size Fits All Approach: Recognizing the Heterogeneity of COPD

The Heterogeneity of Underlying Inflammation in Patients With COPD
Pulmonology
expert video

The Heterogeneity of Underlying Inflammation in Patients With COPD

What Differentiates COPD Exacerbations From Asthma Exacerbations?
Pulmonology
expert video

What Differentiates COPD Exacerbations From Asthma Exacerbations?

What Do We Know About Type 2 Inflammation in COPD?
Pulmonology
expert video

What Do We Know About Type 2 Inflammation in COPD?

Complex EoE Pathophysiology Beyond Esophageal Eosinophilia
Gastroenterology
expert video

Complex EoE Pathophysiology Beyond Esophageal Eosinophilia

Esophageal Dilation Does Not Impact Underlying Inflammation in EoE
Gastroenterology
expert video

Esophageal Dilation Does Not Impact Underlying Inflammation in EoE

Food Bolus Impaction: An Opportunity to Diagnose EoE
Gastroenterology
expert video

Food Bolus Impaction: An Opportunity to Diagnose EoE

Gap in Care Leads to Progression of Fibrosis in EoE
Gastroenterology
expert video

Gap in Care Leads to Progression of Fibrosis in EoE

Impact of Delayed EoE Diagnosis on Disease Progression and QoL
Gastroenterology
expert video

Impact of Delayed EoE Diagnosis on Disease Progression and QoL

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

Sanofi | Regeneron Logo

© 2024 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-US-2305040 v3.0-P Exp. Date: 11/24/2025

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: United StatesChange country/region